UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   Washington, D.C.  20549

                          FORM 10-Q


     (X)    Quarterly Report Pursuant to Section 13 or
            15(d) of the Securities Exchange Act of 1934

       For the second quarter period ended February 29, 2000

                            or

     ( )   Transition Report Pursuant to Section 13 or
           15(d) of the Securities Exchange Act of 1934.

       For the transition period from ____________ to  ____________

     Commission File Number   0-20212

                          ARROW INTERNATIONAL, INC.
                          -------------------------
           (Exact name of registrant as specified in its charter)


             Pennsylvania                        23-1969991
             ------------                        ----------
 (State or other jurisdiction of                (I.R.S. Employer
  incorporation or organization)               Identification No.)


 2400 Bernville Road, Reading, Pennsylvania         19605
 ------------------------------------------         -----
 (Address of principal executive offices)         (Zip Code)


Registrant's telephone number, including area code:(610) 378-0131
                                                   --------------

Indicate by check mark whether the registrant (1) has  filed
all  reports required to be filed by Section 13 or 15(d)  of
the Securities Exchange Act of 1934 during the preceding  12
months  (or for such shorter period that the registrant  was
required to file such reports), and (2) has been subject  to
such  filing requirements for the past 90 days.   Yes  X  No
                                                       -    -

Indicate  the number of shares outstanding of  each  of  the
issuer's   classes  of  common  stock,  as  of  the   latest
practicable date.

       Class                  Shares outstanding at April 12, 2000
       -----                  ------------------------------------
Common Stock, No Par Value                 22,261,503


</PAGE>



<PAGE>
                       ARROW INTERNATIONAL, INC.

                           Form 10-Q Index


[S]                                                          Page
                                                             ----
PART I.  FINANCIAL INFORMATION                             [C]

         Item 1.  Financial Statements

         Consolidated Balance Sheets at February 29, 2000
         and August 31, 1999                                  3-4

         Consolidated Statements of Income                    5-6

         Consolidated Statements of Cash Flows                7-8

         Consolidated Statements of Comprehensive Income       9

         Notes to Consolidated Financial Statements          10-14

         Item 2.  Management's Discussion and Analysis of
                  Financial Condition and Results of
                  Operations                                 15-23

         Item 3.  Quantitative and Qualitative Disclosures
                  About Market Risk                           24


PART II. OTHER INFORMATION

         Item 4.  Submission of Matters to a Vote of Security
                  Holders                                     25

         Item 6.  Exhibits and Reports on Form 8-K            26


Signature                                                     27

Exhibit Index                                                 28



                             -2-
</PAGE>


<PAGE>

PART I - FINANCIAL INFORMATION


Item 1. Financial Statements

<TABLE>
<CAPTION>

                    ARROW INTERNATIONAL, INC.
                   CONSOLIDATED BALANCE SHEETS

                         (In thousands)
                           (Unaudited)


                                      February 29,  August 31,
                                          2000        1999
                                      -----------   ---------
<S>                                   <C>            <C>

ASSETS
Current assets:
 Cash and cash equivalents             $   5,736    $   3,939
 Accounts receivable, net                 74,337       70,467
 Inventories                              77,065       74,809
 Prepaid expenses and other               16,906       16,242
 Deferred income taxes                     2,181        2,018
                                       ---------    ---------
  Total current assets                   176,225      167,475
                                       ---------    ---------

Property, plant and equipment:
 Total property, plant and equipment     214,855      204,939

 Less accumulated depreciation           (95,146)     (88,005)
                                       ---------    ---------
                                         119,709      116,934
                                       ---------    ---------

 Goodwill, net                            39,697       35,698
 Intangible and other assets, net         41,620       33,487
 Deferred income taxes                     5,520        4,738
                                       ---------    ---------
  Total other assets                      86,837       73,923
                                       ---------    ---------
  Total assets                         $ 382,771    $ 358,332
                                       =========    =========
</TABLE>

   See accompanying notes to consolidated financial statements

                            Continued

                               -3-
</PAGE>

<PAGE>


<TABLE>
<CAPTION>

                    ARROW INTERNATIONAL, INC.
             CONSOLIDATED BALANCE SHEETS, Continued

              (In thousands, except share amounts)
                           (Unaudited)


                                        February 29,       August 31,
                                           2000              1999
                                        ------------       ----------
<S>                                     <C>                <C>

LIABILITIES
Current liabilities:
 Current maturities of long-term debt    $      471        $      470
 Notes payable                               53,530            32,802
 Accounts payable                             8,861            10,028
 Cash overdrafts                                569               394
 Accrued liabilities                         11,018             8,707
 Accrued compensation                         6,312             6,223
 Accrued income taxes                         4,094               950
  Total current liabilities                  84,855            59,574
                                         ----------        ----------
Long-term debt                               10,066            11,105
Accrued postretirement benefit obligation     9,724             9,486

Commitments and contingencies                    -                 -


SHAREHOLDERS' EQUITY

 Preferred Stock, no par value;
  5,000,000 shares authorized;
  none issued                                    -                 -
 Common Stock, no par value;
  50,000,000 shares authorized;
  issued 26,478,813 shares                   45,661            45,661
 Retained earnings                          269,784           250,931
  Less treasury stock at cost:
  4,072,070 and 3,420,970 shares,
  respectively                              (31,543)          (12,618)
 Accumulated other comprehensive
  expense                                    (5,776)           (5,807)
                                          ---------         ---------
  Total shareholders' equity                278,126           278,167
                                          ---------         ---------
  Total liabilities and
   shareholders' equity                   $ 382,771         $ 358,332
                                          =========         =========
</TABLE>


   See accompanying notes to consolidated financial statements

                               -4-
</PAGE>


<PAGE>

<TABLE>
<CAPTION>


                    ARROW INTERNATIONAL, INC.
                CONSOLIDATED STATEMENTS OF INCOME

       (In thousands, except share and per share amounts)
                           (Unaudited)


                                     For the Three Months Ended
                                     --------------------------
                                     February 29,   February 28,
                                       2000           1999
                                     ------------   ------------
<S>                                  <C>            <C>

Net sales                              $  80,601      $  74,274
Cost of goods sold                        37,830         35,625
                                       ---------      ---------
 Gross profit                             42,771         38,649

Operating expenses:
 Research, development and engineering     4,753          5,440
 Selling, general and administrative      18,876         17,369
 Special charge                               -           4,139
                                       ---------      ---------
 Operating income                         19,142         11,701
                                       ---------      ---------

Other expenses (income):
 Interest expense, net of
    amounts capitalized                      589            502
 Interest income                            (139)           (72)
 Other, net                                  167         (1,807)
                                       ---------      ---------
 Other expenses (income), net                617         (1,377)
                                       ---------      ---------

Income before income taxes                18,525         13,078
Provision for income taxes                 6,299          4,773
                                       ---------      ---------
  Net income                           $  12,226      $   8,305
                                       =========      =========


Basic and diluted earnings
  per common share                     $     .54      $     .36
                                       =========      =========
Cash dividends per common share        $     .06      $    .055
                                       =========      =========

Weighted average shares outstanding   22,540,498     23,224,326
                                      ==========     ==========
</TABLE>








   See accompanying notes to consolidated financial statements

                               -5-

</PAGE>


<PAGE>

<TABLE>
<CAPTION>


                    ARROW INTERNATIONAL, INC.
                CONSOLIDATED STATEMENTS OF INCOME

        (In thousands, except share and per share amounts)
                           (Unaudited)


                                     For the Six Months Ended
                                     ------------------------
                                     February 29,   February 28,
                                       2000           1999
                                     ------------   ------------
<S>                                  <C>             <C>

Net sales                              $ 157,318     $  142,359
Cost of goods sold                        73,167         66,661
                                       ---------     ----------
 Gross profit                             84,151         75,698

Operating expenses:
 Research, development and engineering    10,124         10,751
 Selling, general and administrative      37,119         34,224
 Special charge                            3,320          4,139
                                       ---------      ---------
 Operating income                         33,588         26,584
                                       ---------      ---------

Other expenses (income):
 Interest expense, net of
    amounts capitalized                    1,052            724
 Interest income                            (288)          (163)
 Other, net                                  327         (3,030)
                                       ---------      ---------
 Other expenses (income), net              1,091         (2,469)
                                       ---------      ---------

Income before income taxes                32,497         29,053
Provision for income taxes                11,049         10,604
                                       ---------      ---------

 Net income                            $  21,448     $   18,449
                                       =========     ==========



Basic and diluted earnings
   per common share                    $     .94     $      .80
                                       =========     ==========
Cash dividends per common share        $    .115     $     .105
                                       =========     ==========

Weighted average shares outstanding   22,719,865     23,224,554
                                      ==========     ==========

</TABLE>









   See accompanying notes to consolidated financial statements

                               -6-
</PAGE>


<PAGE

<TABLE>
<CAPTION>

                    ARROW INTERNATIONAL, INC.
              CONSOLIDATED STATEMENTS OF CASH FLOWS

                         (In thousands)
                           (Unaudited)

                                          For the Six Months Ended
                                          ------------------------
                                         February 29,   February 28,
                                             2000          1999
                                         ------------   ------------
<S>                                      <C>            <C>

Cash flows from operating activities:
 Net income                                $  21,448     $   18,449

Adjustments to reconcile net income to
 net cash provided by operating activities:
 Depreciation                                  7,736          7,504
 Special charge                                3,320          4,139
 Amortization of intangible assets
   and goodwill                                2,207          1,472
 Amortization of unearned compensation            -              44
 Deferred income taxes                          (945)        (2,267)
 Unrealized holding(gain)loss on securities     (585)           470
 Other                                           210            196
 Changes in operating assets and liabilities:
  Accounts receivable, net                    (4,234)        (9,107)
  Inventories                                 (2,803)        (1,195)
  Prepaid expenses and other                  (1,508)        (2,332)
  Accounts payable and accrued liabilities       255          3,275
  Accrued compensation                           128         (1,664)
  Accrued income taxes                         3,116         (1,106)
                                          ----------     ----------
  Total adjustments                            6,897           (571)
                                          ----------     ----------
  Net cash provided by operating activities   28,345         17,878
                                          ----------     ----------

Cash flows from investing activities:
 Capital expenditures                        (11,203)        (9,887)
 (Increase) decrease in intangible
    and other assets                          (3,505)           223
 Cash paid for business acquired, net        (10,980)       (26,364)
                                          ----------     ----------
  Net cash used in investing activities      (25,688)       (36,028)

Cash flows from financing activities:
 Increase in notes payable                    21,030         21,002
 Principal payments of long-term debt           (315)          (764)
 Increase (decrease) in book overdrafts          175            802
 Dividends paid                               (2,595)        (2,439)
 Proceeds from stock options exercised            25             -
 Purchase of treasury stock                  (18,950)           (36)
                                          ----------     ----------
  Net cash provided by (used in)
     financing activities                       (630)        18,565

Effect of exchange rate changes on cash
 and cash equivalents                           (230)            69

Net change in cash and cash equivalents        1,797            484
Cash and cash equivalents at beginning of year 3,939          4,652
                                          ----------     ----------
Cash and cash equivalents
   at end of period                      $     5,736    $     5,136
                                         ===========    ===========
</TABLE>



   See accompanying notes to consolidated financial statements

                            Continued

                               -7-
</PAGE>


<PAGE>

<TABLE>
<CAPTION>
                    ARROW INTERNATIONAL, INC.
        CONSOLIDATED STATEMENTS OF CASH FLOWS, Continued

                         (In thousands)
                           (Unaudited)



                                            For the Six Months Ended
                                           ----------------------------
                                           February 29,    February 28,
                                               2000            1999
                                           ------------    ------------
<S>                                        <C>              <C>

Supplemental disclosure of cash flow information:

 Cash paid during the year for:
  Interest (net of amounts capitalized)    $     1,052      $     724
  Income taxes                             $     9,493      $  13,379

Supplemental schedule of non cash investing and financing
activities:

 Estimated fair value of assets acquired,
  net of cash acquired                     $    13,289      $  27,586
 Cash paid for assets, net of cash acquired,
  of $386 and $0, respectively                  10,980         26,364
                                           -----------      ---------
 Liabilities assumed                       $     2,309      $   1,222
                                           ===========      =========


 Cash paid for business acquired:
  Working capital                          $      (876)     $   5,466
  Property, plant and equipment                     54            300
  Goodwill, intangible assets and in-process
     research and development                   12,188         20,598
                                           -----------      ---------
                                           $    11,366      $  26,364
                                           ===========      =========


</TABLE>

   See accompanying notes to consolidated financial statements

                               -8-
</PAGE>



<PAGE>

<TABLE>
<CAPTION>

                    ARROW INTERNATIONAL, INC.
         CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

                         (In thousands)
                           (Unaudited)



                                           For the Three Months Ended
                                          ----------------------------
                                          February 29,    February 28,
                                              2000            1999
                                          ------------    ------------

Net income                                  $  12,226       $   8,305

Other comprehensive income (expense):
 Currency translation adjustments                (796)         (1,222)
 Unrealized holding gain (loss) on securities,
    net of tax ($(734) and $299, respectively)  1,181            (452)
                                            ---------       ---------

Other comprehensive income (expense)              385          (1,674)
                                            ---------       ---------

Total comprehensive income                  $  12,611       $   6,631
                                            =========       =========


                                           For the Six Months Ended
                                          ---------------------------
                                          February 29,    February 28,
                                              2000           1999
                                          ------------    ------------
<S>                                       <C>             <C>

Net income                                  $  21,448       $  18,449

Other comprehensive income (expense):
 Currency translation adjustments                (939)            786
 Unrealized holding gain (loss) on securities,
    net of tax ($(585) and $470, respectively)    970            (711)
                                            ---------       ---------

Other comprehensive income (expense)               31              75
                                            ---------       ---------

Total comprehensive income                  $  21,479       $  18,524
                                            =========       =========

</TABLE>




   See accompanying notes to consolidated financial statements

                               -9-
</PAGE>



<PAGE>

                    ARROW INTERNATIONAL, INC.
           Notes to Consolidated Financial Statements

            (In thousands, except per share amounts)
                           (Unaudited)


Note 1 - Basis of Presentation

These  unaudited  consolidated financial statements  include  all
adjustments, consisting only of normal recurring accruals,  which
management  considers necessary for a fair  presentation  of  the
Company's consolidated financial position, results of operations,
and  cash  flows for the interim periods presented.  Results  for
the interim periods are not necessarily indicative of results for
the  entire  year.  Such statements are presented  in  accordance
with  the  requirements  of Form 10-Q  and  do  not  include  all
disclosures  normally required by generally  accepted  accounting
principles or those normally made on Form 10-K.


Note 2 - Inventories



Inventories are summarized as follows:

<TABLE>
<CAPTION>


                                     February 29,  August 31,
                                        2000          1999
                                     ------------  ----------
<S>                                   <C>           <C>

 Finished goods                      $  26,495      $  31,779
 Semi-finished goods                    16,778         12,654
 Work-in-process                        10,816         10,528
 Raw materials                          22,976         19,848
                                     ---------      ---------

                                     $  77,065      $  74,809
                                     =========      =========
</TABLE>

Note 3 - Commitments and Contingencies

The  Company is a party to certain legal actions arising  in  the
ordinary   course  of  its  business.   Based  upon   information
presently available to the Company, the Company believes  it  has
adequate  legal defenses or insurance coverage for these  actions
and  that the ultimate outcome of these actions would not have  a
material  adverse  effect on the Company's business,  results  of
operations, or financial position.







                            Continued

                              -10-
</PAGE>


<PAGE>

                    ARROW INTERNATIONAL, INC.
           Notes to Consolidated Financial Statements

            (In thousands, except per share amounts)
                           (Unaudited)




Note 4 - Related Party Transactions

During  the  three and six months ended February  29,  2000,  the
Company  made  purchases amounting to $55 and $79,  respectively,
from   Precision  Medical  Products,  Inc.  ("PMP"),   a   former
subsidiary of Arrow Precision Products, Inc. ("Precision"), which
is  related  to  the  Company through common ownership.   PMP  is
currently  owned  by  certain  former  management  employees   of
Precision,  including T. Jerome Holleran,  who  serves  as  PMP's
Chairman  and  Chief  Executive Officer and as  Secretary  and  a
Director of the Company.


Note 5 - Accounting Policies

Reclassifications

Certain prior period information has been reclassified for
comparative purposes.


Note 6 - Business Acquisitions:

On  September  1, 1999, the Company completed the acquisition  of
Sometec,  S.A.,  a French development company that  has  recently
developed   a  non-invasive  esophageal  ultrasound  probe   that
continuously measures descending aortic blood flow, for  $11,400.
The  acquisition has been accounted for using the purchase method
of accounting.  The allocation of the purchase price was prepared
on  a preliminary basis pending completion of the valuation.  The
excess of the purchase price over the estimated fair value of the
net  assets  acquired of approximately $4,747 is being  amortized
over  a period of 20 years.  Intangible assets acquired are being
amortized  over a period of 10 years.  The results of  operations
of  this  business  are  included in the  Company's  consolidated
financial  statements  from the date  of  acquisition.   Proforma
amounts  are  not presented as this acquisition has  no  material
effect  on  the  Company's  results of  operations  or  financial
condition.


Note 7 - Special Charge:

In  the first quarter of fiscal 2000, the Company recorded a non-
cash  pre-tax special charge of $3,320 ($2,191 after-tax or  $.10
per  basic  and  diluted common share) related primarily   to   a
write-down  for   the   in-process   research   and   development
acquired in




                            Continued

                              -11-
</PAGE>


<PAGE>
                    ARROW INTERNATIONAL, INC.
           Notes to Consolidated Financial Statements

            (In thousands, except per share amounts)
                           (Unaudited)



Note 7 - Special Charge: (Continued)

connection with the Company's recent acquisition of Sometec, S.A.
(see Note 6 of these Notes to Consolidated Financial Statements).
The  technology  acquired  is a compact  monitoring  device  that
measures  and  monitors the descending aortic blood  flow  during
anesthesia  and  intensive care.  The device  provides  real-time
aortic blood flow (a measurement of cardiac output) by using both
pulsed Doppler for measuring blood velocity and M-mode ultrasound
to accurately measure the aortic diameter.  The monitoring system
consists  of four main components: the main console (monitor),  a
transesophageal  probe, a disposable jacket  and  an  articulated
probe  holder.   The  monitor  provides  the  physician  with   a
continuous display of a patient's hemodynamic profile,  including
aortic  blood  flow,  heart rate, stroke volume,  peak  velocity,
acceleration,  left  ventricular  ejection  time   and   systemic
vascular  resistance.   To  facilitate  use  of  this  device,  a
disposable jacket, containing an acoustic gel, is placed over the
probe utilizing a special vacuum mounting tool supplied with  the
jacket.  The Company believes that the speed and ease of  use  of
this  new noninvasive measurement technique has the potential  of
establishing  cardiac output as a frequently used physician  tool
with  value  similar  to blood pressure, EKG and  pulse  oximetry
measurements.   In  accordance with SFAS No. 2,  "Accounting  for
Research and Development Costs" and FIN No. 4, "Applicability  of
SFAS No. 2 to Business Combinations Accounted for by the Purchase
Method",  these costs related to the special charge were  charged
to  expense at the date of consummation of the acquisition.   The
value  assigned  to  purchase Sometec in-process  technology  was
based  on  a  valuation  prepared by an  independent  third-party
appraisal company.  Each of the technologies under development at
the   date   of   acquisition  was  reviewed  for   technological
feasibility, stage of completeness at the acquisition  date,  and
scheduled  release dates of products employing the technology  to
determine   whether   the  technology  was  complete   or   under
development.    At  the  acquisition  date,  the   research   and
development project was estimated to be 75% complete.  Incomplete
development efforts at the time of acquisition included  improved
portability,   software  development  and  development   of   the
disposable sheath.  The valuation was based on the estimated cash
flows  resulting from commercially viable products discounted  to
present  value using a risk adjusted after-tax discount  rate  of
22%.  The research and development costs and the net cash inflows
from these projects are expected to commence within a year of the
acquisition  date.   However, while the  Company  believes  these
projects will be completed as planned, the Company cannot  assure
you  that  they will be completed on schedule or, once completed,
that  the  new  products resulting from these  projects  will  be
successfully  introduced into the marketplace.  The Company  does
not  anticipate material adverse changes from historical pricing,
margins and expense levels as a result of the introduction of the
new technologies related to the projects.



                              -12-
</PAGE>


<PAGE>


                    ARROW INTERNATIONAL, INC.
           Notes to Consolidated Financial Statements

            (In thousands, except per share amounts)
                           (Unaudited)


Note 8 - Segment Reporting:

In  the  fourth quarter of fiscal 1999, the Company adopted  SFAS
No. 131, "Disclosures about Segments of an Enterprise and Related
Information".   SFAS No. 131 changes the way the Company  reports
information  about  its  operating segments  to  the  "management
approach".   The  management  approach  is  based  on   the   way
management  organizes  the  segments within  the  enterprise  for
making  operating  decisions  and  assessing  performance.    The
Company  operates  as a single reportable segment.   The  Company
operates  in four main geographic regions, therefore, information
by product category and geographic areas is presented below.

The  following  table  provides quarterly information  about  the
Company's sales by product category:
<TABLE>
<CAPTION>


                    Three Months Ended    Three Months Ended
                     February 29, 2000     February 28, 1999
                    ------------------    ------------------
                    Critical   Cardiac    Critical   Cardiac
                      Care       Care       Care        Care
                    --------   -------    --------   -------
<S>                 <C>        <C>        <C>        <C>
Sales to external
  customers         $ 66,600   $  14,000  $  59,900  $ 14,400


The following tables present quarterly information about
geographic areas:

                       Three Months Ended February 29, 2000
                 -----------------------------------------------------------
                  United  Asia and         Other
                  States  Africa   Europe  Foreign Eliminations Consolidated
                 -------  -------- ------  ------- ------------ ------------
<S>              <C>      <C>      <C>     <C>      <C>         <C>
Sales to unaffiliated
  customers      $ 61,300 $10,200  $6,900  $2,200    $  -       $   80,600


                       Three Months Ended February 28, 1999
                 -----------------------------------------------------------
                  United  Asia and         Other
                  States  Africa   Europe  Foreign Eliminations Consolidated
                 -------  -------- ------  ------- ------------ ------------
Sales to unaffiliated
  customers      $ 56,300 $ 8,800  $7,200 $2,000     $  -       $   74,300

</TABLE>

Export sales to unaffiliated customers were $9,300 and $9,100 for
the three months ended February 29, 2000 and February 28,  1999,
respectively



                              -13-
</PAGE>


<PAGE>


                    ARROW INTERNATIONAL, INC.
           Notes to Consolidated Financial Statements

            (In thousands, except per share amounts)
                           (Unaudited)



Note 8 - Segment Reporting (continued):


The  following table provides year-to-date information about  the
Company's sales by product category:

<TABLE>
<CAPTION>


                     Six Months Ended      Six Months Ended
                     February 29, 2000     February 28, 1999
                    -------------------    -----------------
                    Critical    Cardiac    Critical  Cardiac
                      Care       Care       Care        Care
                    --------    -------    --------  -------
<S>                 <C>         <C>        <C>       <C>
Sales to external
  customers         $130,500   $ 26,800    $116,000 $ 26,400



The following tables present year-to-date information about
geographic areas:


                        Six Months Ended February 29, 2000
                 ------------------------------------------------------------
                  United  Asia and         Other
                  States  Africa   Europe  Foreign  Eliminations Consolidated
                 -------  -------- ------  -------  ------------ ------------
<S>              <C>      <C>      <C>     <C>         <C>        <C>
Sales to unaffiliated
  customers      $119,300 $19,500  $14,200 $ 4,300     $  -       $ 157,300



                        Six Months Ended February 28, 1999
                 ------------------------------------------------------------
                  United  Asia and         Other
                  States  Africa   Europe  Foreign  Eliminations Consolidated
                 -------  -------- ------  -------  ------------ ------------
Sales to unaffiliated
  customers      $108,700 $16,000  $14,000 $ 3,700     $  -       $ 142,400

</TABLE>

Export  sales to unaffiliated customers were $17,300 and  $16,800
for the six months ended February 29, 2000 and February 28, 1999,
respectively.









                              -14-
</PAGE>


<PAGE>
                    ARROW INTERNATIONAL, INC.


Item 2.  Management's Discussion and Analysis of Financial Condition
         and Results of Operations

The   following   discussion  includes  certain   forward-looking
statements.   Such forward-looking statements are  subject  to  a
number  of  factors, including material risks, uncertainties  and
contingencies,  which  could  cause  actual  results  to   differ
materially from the forward-looking statements.  For a discussion
of  important factors that could cause actual results  to  differ
materially from the forward-looking statements, see Exhibit  99.1
to  this  Report  and the Company's periodic  reports  and  other
documents filed with the Securities and Exchange Commission.

                      Results of Operations

Three  Months  Ended February 29, 2000 Compared to  Three  Months
Ended February 28, 1999

Net  sales for the three months ended February 29, 2000 increased
by  $6.3 million, or 8.5%, to $80.6 million from $74.3 million in
the  same  period  last  year.  Net sales represent  gross  sales
invoiced to customers, plus royalty income, less certain  related
charges,  including freight costs, discounts, returns  and  other
allowances.   This  increase was due  primarily  to  higher  unit
volume  of  the  Company's central venous and specialty  catheter
products.   Sales  of critical care products increased  11.2%  to
$66.6  million  from $59.9 million in the comparable  prior  year
period due primarily to increased shipments of central venous and
special   catheters  and  drug  infusion  pumps.   Cardiac   care
procedure  product  sales decreased to $14.0 million  from  $14.4
million,  a  decrease  of  2.8% from the  comparable  prior  year
period,  due primarily to decreased sales of intra-aortic balloon
("IAB") products.  International sales increased by 5.6% to $28.6
million  from  $27.1 million in the same prior  year  period  and
represented  35.5%  of  net  sales,  compared  to  36.5%  in  the
comparable  fiscal  1999  period,  principally  as  a  result  of
increased  sales  of  central  venous  catheters.  The  increased
strength  of the U.S. dollar, relative to currencies in countries
where the Company operates direct sales subsidiaries, reduced net
sales for the quarter by $0.1 million.

Gross profit increased 10.7% to $42.8 million in the three months
ended  February 29, 2000 compared to $38.6 million  in  the  same
period  of  fiscal  1999.  As a percentage of  net  sales,  gross
profit  increased to 53.1% during the three months ended February
29,  2000 from 52.0% in the comparable prior year period, due  to
product and distribution mix and lower costs of production  as  a
percentage of sales.





                              -15-
</PAGE>


<PAGE>
                    ARROW INTERNATIONAL, INC.


Research, development and engineering expenses decreased by 12.6%
to  $4.8 million in the three months ended February 29, 2000 from
$5.4  million  in  the  comparable  prior  year  period.   As   a
percentage  of net sales, these expenses decreased in the  second
quarter  of  fiscal 2000 to 5.9%, compared to 7.3%  in  the  same
period in fiscal 1999.  These decreases are primarily a result of
reduced clinical study activity resulting from the March 8,  2000
Food  and  Drug Administration ("FDA") clearance of the Company's
510(k)   application  to  market   ARROWg+ard[REGISTERED] Blue
Plus<Trandemark> the Company's    newest   formulation  of  its
antimicrobial treatment  for central venous catheters.

Selling, general and administrative expenses increased by 8.7% to
$18.9  million in the three months ended February 29,  2000  from
$17.4  million  in  the  comparable period  of  fiscal  1999  and
remained  constant as a percentage of net sales at 23.4%.   These
expenses  increased  to support higher sales levels  and  include
higher  amortization expense due to the acquisition of the assets
of  the  cardiac assist division of C.R. Bard, Inc.  in  December
1998 and the acquisition of Sometec, S.A. in September 1999.

In  the  second  quarter of fiscal 1999, the Company  recorded  a
special  charge  related primarily to a write-down  for  the  in-
process research and development acquired in connection with  the
Company's  recent  acquisition of Sometec.   Further  information
concerning  this  special  charge  is  disclosed  later  in  this
Management's  Discussion  and Analysis  under  the  caption  "Six
Months  Ended  February 29, 2000 Compared  to  Six  Months  Ended
February 28, 1999."

Principally due to the above factors, operating income  increased
in  the  second quarter of fiscal 2000 by 63.6% to $19.1  million
from   $11.7   million  in  the  comparable  prior  year   period
principally  due to foreign exchange gains and losses  associated
with the Company's direct sales subsidiaries.

Other  expenses  (income),  net, decreased  to  $0.6  million  of
expense  in the second quarter of fiscal 2000 from $(1.4) million
of  income in the comparable prior year period principally due to
foreign  exchange gains and losses associated with the  Company's
direct sales subsidiaries.  Other expenses (income), net, consist
principally  of  interest income, interest  expense  and  foreign
exchange  gains  and losses associated with the Company's  direct
sales subsidiaries.

As  a result of the factors discussed above, income before income
taxes increased in the second quarter of fiscal 2000 by 41.7%  to
$18.5  million  from $13.1 million in the comparable  prior  year
period.   For  the second quarter of fiscal 2000,  the  Company's
effective income tax rate was 34.0%, a decrease from 36.5% in the
same period of fiscal 1999, principally as a result of the recent
completion of tax examinations through August 31, 1998.











                              -16-
</PAGE>


<PAGE>

                    ARROW INTERNATIONAL, INC.




Net  income  in  the second quarter of fiscal 2000  increased  by
47.2%  to $12.2 million from $8.3 million in the comparable prior
year  period  primarily as a result of the above factors.   As  a
percentage  of  net sales, net income represented  15.2%  in  the
three  months ended February 29, 2000, compared to 11.2%  in  the
comparable prior year period.

Basic and diluted earnings per common share were $.54 and $.36 in
the  second  quarters  of  fiscal 2000  and  1999,  respectively.
Weighted   average   common  shares  outstanding   decreased   to
22,540,498  in the second quarter of fiscal 2000 from  23,224,326
in  the comparable prior year period as a result of the Company's
previously  announced share repurchase program, which remains  in
effect.







                              -17-
</PAGE>


<PAGE>

                    ARROW INTERNATIONAL, INC.


Six  Months Ended February 29, 2000 Compared to Six Months Ended
February 28, 1999

Net sales for the six months ended February 29, 2000 increased by
$14.9 million, or 10.5%, to $157.3 million from $142.4 million in
the same period last year.  This increase was due primarily to an
increase  in  unit  volume in the Company's  central  venous  and
specialty  catheter  products.  Sales of critical  care  products
increased  12.5%  to $130.5 million from $116.0  million  in  the
comparable prior year period due primarily to increased shipments
of  central venous and specialty catheter products.  Cardiac care
product  sales increased to $26.8 million from $26.4 million,  an
increase  of  1.5%  from the comparable prior  year  period,  due
primarily  to  a  decrease  in unit shipments  of  IAB  products.
International sales increased by 9.5% to $55.3 million from $50.5
million in the same prior year period, and decreased to 35.2%  of
net  sales for the six months ended February 29, 2000 from  35.5%
in  the comparable period of fiscal 1999, principally as a result
of  increased sales of central venous catheters and IAB products.
The decreased strength of the U.S. dollar, relative to currencies
in   countries   where   the  Company   operates   direct   sales
subsidiaries, increased net sales for the six month period  ended
February 29, 2000 by $0.2 million.

Gross  profit increased 11.1% to $84.2 million in the six  months
ended  February 29, 2000 compared to $75.7 million  in  the  same
period  of  fiscal  1999.  As a percentage of  net  sales,  gross
profit  increased to 53.5% during the six months  ended  February
29,  2000 from 53.2% in the comparable period of fiscal 1999  due
primarily  to  product and distribution mix and  lower  costs  of
production as a percentage of sales.

Research, development and engineering expenses decreased by  5.8%
to  $10.1 million in the six months ended February 29, 2000  from
$10.8  million  in  the  comparable  prior  year  period.   As  a
percentage  of net sales, these expenses decreased in  the  first
half  of fiscal 2000 to 6.4%, compared to 7.6% in the same period
in  fiscal 1999, primarily as a result of reduced clinical  study
activity  resulting from the March 8, 2000 FDA clearance  of  the
Company's 510(k) application to market ARROWg+ard[REGISTERED] Blue
Plus<TRADE MARK>.

Selling, general and administrative expenses increased by 8.5% to
$37.1  million  in the six months ended February  29,  2000  from
$34.2  million in the comparable prior year period and  decreased
as a percentage of net sales to 23.5% in the first half of fiscal
2000  from  24.0% in the comparable period of fiscal  1999.   The
increased  expenses  are  due primarily  to  additional  expenses
related  to  the acquisitions of the cardiac assist  division  of
C.R.  Bard,  Inc. in December 1998 and Sometec S.A. in  September
1999.




                              -18-
</PAGE>


<PAGE>
                    ARROW INTERNATIONAL, INC.


In  the first quarter of fiscal 2000, the Company recorded a non-
cash  pre-tax special charge of $3.3 million ($2.2 million after-
tax or $.10 per basic and diluted common share) related primarily
to  a  write-down  for  the in-process research  and  development
acquired  in connection with the Company's recent acquisition  of
Sometec,  S.A.  (see  Note 6 of Notes to  Consolidated  Financial
Statements).   The  technology acquired is a  compact  monitoring
device  that  measures and monitors the descending  aortic  blood
flow  during anesthesia and intensive care.  The device  provides
real-time aortic blood flow (a measurement of cardiac output)  by
using both pulsed Doppler for measuring blood velocity and M-mode
ultrasound  to  accurately  measure  the  aortic  diameter.   The
monitoring  system  consists of four main  components:  the  main
console  (monitor), a transesophageal probe, a disposable  jacket
and  an  articulated  probe  holder.  The  monitor  provides  the
physician  with  a continuous display of a patient's  hemodynamic
profile, including aortic blood flow, heart rate, stroke  volume,
peak  velocity, acceleration, left ventricular ejection time  and
systemic vascular resistance.  To facilitate use of this  device,
a  disposable jacket, containing an acoustic gel, is placed  over
the  probe utilizing a special vacuum mounting tool supplied with
the  jacket.  The Company believes that the speed and ease of use
of  this  new noninvasive measurement technique has the potential
of  establishing  cardiac output as a frequently  used  physician
tool with value similar to blood pressure, EKG and pulse oximetry
measurements.   In  accordance with SFAS No. 2,  "Accounting  for
Research and Development Costs" and FIN No. 4, "Applicability  of
SFAS No. 2 to Business Combinations Accounted for by the Purchase
Method",  these costs related to the special charge were  charged
to  expense at the date of consummation of the acquisition.   The
value  assigned  to  purchase Sometec in-process  technology  was
based  on  a  valuation  prepared by an  independent  third-party
appraisal company.  Each of the technologies under development at
the   date   of   acquisition  was  reviewed  for   technological
feasibility, stage of completeness at the acquisition  date,  and
scheduled  release dates of products employing the technology  to
determine   whether   the  technology  was  complete   or   under
development.    At  the  acquisition  date,  the   research   and
development project was estimated to be 75% complete.  Incomplete
development efforts at the time of acquisition included  improved
portability,   software  development  and  development   of   the
disposable sheath.  The valuation was based on the estimated cash
flows  resulting from commercially viable products discounted  to
present  value using a risk-adjusted after-tax discount  rate  of
22%.  The research and development costs and the net cash inflows
from these projects are expected to commence within a year of the
acquisition  date.   However, while the  Company  believes  these
projects will be completed as planned, the Company cannot  assure
you  that  they will be completed on schedule or, once completed,
that  the  new  products resulting from these  projects  will  be
successfully  introduced into the marketplace.  The Company  does
not  anticipate material adverse changes from historical pricing,
margins and expense levels as a result of the introduction of the
new technologies related to the projects.



                              -19-
</PAGE>


<PAGE>

                    ARROW INTERNATIONAL, INC.


In the second quarter of fiscal 1999, the Company recorded a non-
cash  pre-tax special charge of $4.1 million ($2.6 million after-
tax  or  $.11 per basic and diluted common share) related to  the
purchase  of  in-process intra-aortic balloon  ("IAB")  and  pump
research and development as part of its acquisition of the assets
of  the  cardiac assist division of C.R. Bard, Inc.  The IAB  and
pumps  are class 3 life saving medical devices regulated  by  the
FDA.  In accordance with SFAS No. 2, "Accounting for Research and
Development Costs" and FIN No. 4, "Applicability of SFAS No. 2 to
Business  Combinations  Accounted for by  the  Purchase  Method",
these costs related to the special charge were charged to expense
at  the  date  of  consummation of the  acquisition.   The  value
assigned to this purchased IAB and pump in-process technology was
based  on  a  valuation  prepared by an  independent  third-party
appraisal company.  Each of the technologies under development at
the   date   of   acquisition  was  reviewed  for   technological
feasibility, stage of completeness at the acquisition  date,  and
scheduled  release dates of products employing the technology  to
determine   whether   the  technology  was  complete   or   under
development.    At  the  acquisition  date,  the   research   and
development projects were in various stages of completion ranging
from  50% to 80%.  The valuation was based on the estimated  cash
flows  resulting from commercially viable products discounted  to
present value using risk-adjusted discount rates ranging from 29%
to  32%.   The  research and development costs from the  projects
commenced  within  a  year  of the acquisition  date.   Net  cash
inflows  related to certain of these technologies have  commenced
and  inflows  from other of these technologies  are  expected  to
commence  by the end of fiscal 2000.  While the Company  believes
these  projects will be completed as planned, the Company  cannot
assure  you  that  they will be completed on  schedule  or,  once
completed,  that the new products resulting from  these  projects
will  be  successfully  introduced  into  the  marketplace.   The
Company  does  not  anticipate  material  adverse  changes   from
historical pricing, margins and expense levels as a result of the
introduction of the new technologies related to the projects.

Principally due to the above factors, operating income  increased
in  the first half of fiscal 2000 by 26.3% to $33.6 million  from
$26.6 million in the comparable period of fiscal 1999.

Other  expenses  (income),  net, decreased  to  $1.1  million  of
expense  in  the first half of fiscal 2000 from $2.5  million  of
income  in  the  prior  fiscal year principally  due  to  foreign
exchange  gains  and losses associated with the Company's  direct
sales   subsidiaries.   Other  expenses  (income),  net,  consist
principally  of interest expense and foreign exchange  gains  and
losses associated with the Company's direct sales subsidiaries.

As  a result of the factors discussed above, income before income
taxes  increased  in the first half of fiscal 2000  by  11.9%  to
$32.5  million  from $29.1 million in the comparable  prior  year
period.  The Company's effective income tax rate decreased to 34%
from  36.5% in fiscal 1999, principally as a result of the recent
completion of tax examinations through August 31, 1998.



                              -20-
</PAGE>

<PAGE>
                    ARROW INTERNATIONAL, INC.


Net  income  increased 16.3% to $21.4 million in the  six  months
ended  February 29, 2000 from $18.4 million in the first half  of
fiscal   1999.   As  a  percentage  of  net  sales,  net   income
represented 13.7% during the six months ended February  29,  2000
compared to 13.0% in the comparable period of fiscal 1999.

Basic and diluted earnings per common share were each $.94 in the
six month period ended February 29, 2000, an increase of 17.5% or
$.14  per share, from $.80 per share in the comparable prior year
period  primarily  as  a  result of the above  factors.   Average
shares of common stock outstanding decreased to 22,719,865 in the
first half of fiscal 2000 from 23,224,554 in the comparable prior
period  as  a result of the Company's previously announced  share
repurchase program, which remains in effect.

                 Liquidity and Capital Resources

For the six months ended February 29, 2000, net cash provided  by
operations  was $28.3 million, an increase of $10.5 million  from
the  same  period in the prior year due to higher net income  and
improved   accounts  receivable  collection  efforts.    Accounts
receivable  increased  by $3.9 million in the  six  months  ended
February 29, 2000 compared to a $9.0 million increase in the same
period  of  fiscal 1999.  Accounts receivable, measured  in  days
sales  outstanding during the period, decreased  to  86  days  at
February  29,  2000  from  93  days at  February  28,  1999,  due
principally to an increase in collection efforts of the Company.

Net cash used in the Company's investing activities decreased  to
$25.7  million  in the six months ended February  29,  2000  from
$36.0   million  in  the  comparable  period  of   fiscal   1999,
principally  as a result of the acquisition in the first  quarter
of  fiscal 1999 for $26.4 million of the cardiac assist  division
of  C.R.  Bard, Inc. and the acquisition in the first quarter  of
fiscal 2000 for $11.4 million of Sometec, Inc.

Financing  activities used $.6 million of net  cash  in  the  six
month  period ended February 29, 2000, and provided $18.6 million
of net cash in the comparable period of fiscal 1999.  This change
is  principally attributable to increased use of cash to purchase
shares  of  the  Company's common stock in  the  open  market  in
connection with its previously announced program to repurchase up
to  one  million shares of its common stock.  For the six  months
ending  February 29, 2000, the Company has expended $19.0 million
to  fund  the  repurchase of 651,100 shares of its  common  stock
pursuant  to  this program.  To date, the Company has repurchased
947,800  shares  under  this  program  for  approximately   $27.4
million.  On April 6, 2000, the Company announced approval by the
Company's Board of Directors to extend this program by purchasing
on  the open market up to an additional one million shares of its
common stock.

As  of  February  29,  2000,  the Company  had  U.S  bank  credit
facilities  providing an aggregate of $65.0 million in  revolving
credit,  of  which $24.4 million remained unused.   In  addition,
certain  of  the  Company's  foreign subsidiaries  had  revolving
credit  facilities totaling the U.S. dollar equivalent  of  $24.5
million,  of  which $11.6 million remained unused as of  February
29,   2000.    Incremental  borrowings  under  these   facilities
increased  $20.7 million and $21.0 million during the six  months
ended February 29, 2000 and February 28, 1999, respectively.


                              -21-
</PAGE>

<PAGE>

                    ARROW INTERNATIONAL, INC.


As  a  partial  hedge  against adverse fluctuations  in  exchange
rates,  the  Company  periodically enters into  foreign  currency
exchange contracts with certain major financial institutions.  By
their nature, all such contracts involve risk, including the risk
of   nonperformance   by  counterparties.   Accordingly,   losses
relating to these contracts could have a material adverse  effect
upon  the Company's business, financial condition and results  of
operations.  Based upon the Company's knowledge of the  financial
condition   of   the  counterparties  to  its  existing   forward
contracts,  the  Company  believes that  it  does  not  have  any
material  exposure to any individual counterparty.  The Company's
policy prohibits the use of derivative instruments for trading or
speculative purposes.

During the six month periods ended February 29, 2000 and February
28,  1999,  the  percentage of the Company's  sales  invoiced  in
currencies   other  than  U.S.  dollars  was  24.2%  and   23.6%,
respectively.   As  of  February 29,  2000,  outstanding  foreign
currency  exchange contracts totaling the U.S. dollar  equivalent
of  $7.6  million mature at various dates through May 2000.   The
Company  expects to continue to utilize foreign currency exchange
contracts  to  manage  its exposure, although  there  can  be  no
assurance  that  the  Company's effort in  this  regard  will  be
successful.

Based upon its present plans, the Company believes that operating
cash  flow  and  available credit resources will be  adequate  to
repay  current  portions of long-term debt, to finance  currently
planned  capital  expenditures,  announced  acquisitions,   stock
repurchases  on  the  open  market  and  to  meet  the  currently
foreseeable liquidity needs of the Company.

Overall  effects  of inflation and seasonality on  the  Company's
business during the periods discussed above were not significant.

The  Company expended an aggregate of approximately $1.7  million
and devoted in excess of 1,200 man-days in internal resources  in
fiscal  1999  and 2000 and the first quarter of  fiscal  2000  to
achieve  its  objective of ensuring that the Company's  products,
business systems and support services to customers would continue
to  operate  satisfactorily on and after January  1,  2000.   The
Company  has described in detail its efforts to address the  Year
2000  problem  as it may have related to its business  operations
and  regulation by the Food and Drug Administration in its Annual
Report on Form 10-K for its fiscal year ended August 31, 1999 and
in its other filings with the Securities and Exchange Commission.

Subsequent  to the end of the Company's first quarter  of  fiscal
2000,  the  calendar  changed to the year  2000.   To  date,  the
business  and  operations  of  the Company  have  experienced  no
material  adverse  effects  from the date  change,  nor  has  the
Company  been  notified of any disruptions  or  failures  in  the
systems  of  any  of  its suppliers or customers.   There  is  an
ongoing  risk that Year 2000 related problems could  still  occur
and  the  Company will continue to evaluate these risks; however,
the  Company believes that the Year 2000 issue will not pose  any
significant operational problems for the Company.


                             -22-
</PAGE>

<PAGE>


                    ARROW INTERNATIONAL, INC.


Item 3.    Quantitative and Qualitative Disclosures About Market
Risk.

Financial Instruments:

During  the six month period ended February 29, 2000 and February
28,  1999,  the  percentage of the Company's  sales  invoiced  in
currencies   other  than  U.S.  dollars  was  24.2%  and   23.6%,
respectively.  In addition, a small part of the Company's cost of
goods  sold  is denominated in foreign currencies.   The  Company
enters  into  foreign  currency  forward  contracts,  which   are
derivative   financial   instruments,   with   major    financial
institutions to reduce the effect of these foreign currency  risk
exposures,  primarily on U.S. dollar cash inflows resulting  from
the collection of intercompany receivables denominated in foreign
currencies.  Such transactions occur throughout the year and  are
probable, but not firmly committed.  Forward contracts are marked
to  market  each  accounting period, and the resulting  gains  or
losses  on these contracts are recorded in Other Income / Expense
of  the  Company's  consolidated statements of income.   Realized
gains  and  losses on these contracts are offset by  the  assets,
liabilities and transactions being hedged.  The Company does  not
use  financial  instruments for trading or speculative  purposes.
The  Company  expects  to  continue to utilize  foreign  currency
exchange contracts to manage its exposure, although there can  be
no  assurance that the Company's efforts in this regard  will  be
successful.

Operations  of  the Company are also exposed to,  in  the  normal
course  of  business,  fluctuations  in  interest  rates.    This
interest  rate  risk exposure results from changes in  short-term
U.S. dollar interest rates.

The  Company's  exposure to credit risk consists  principally  of
trade  receivables.  Hospitals and international dealers  account
for a substantial portion of trade receivables and collateral  is
generally   not   required.   The  risk  associated   with   this
concentration  is  limited due to the Company's  on-going  credit
review procedures.

At  February 29, 2000, the Company had forward exchange contracts
to  sell foreign currencies which mature at various dates through
May   2000.  The  following  table  identifies  forward  exchange
contracts  to  sell foreign currencies at February 29,  2000  and
August 31, 1999 as follows:


<TABLE>
<CAPTION>
                           February 29, 2000         August 31, 1999
                         Notional Fair Market     Notional Fair Market
                            Amounts  Value           Amounts   Value
                         -------------------      --------------------
<S>                      <C>         <C>          <C>         <C>

Foreign currency: (U.S. Dollar Equivalents)

 Japanese yen              $2,361  $ 2,304          $5,698   $ 5,855
 Canadian dollars           1,275    1,276           1,115     1,108
 Greek drachmas             1,997    2,024           1,571     1,603
 Mexican peso               1,447    1,494           1,012     1,064
 African rand                 477      473           1,270     1,314

                           ------  -------         -------   -------
                           $7,557  $ 7,571         $10,666   $10,944
                           ======  =======         =======   =======



</TABLE>


                              -23-
</PAGE>





                        ARROW INTERNATIONAL, INC.

PART II.   OTHER INFORMATION


Item 4.    Submission of matters to a vote of security holders.

       (a) The Company held its annual meeting of shareholders on
           January 19, 2000.

       (b) At the annual meeting, the following matters were voted upon:
          (i)  the election of three directors (in connection with which (A)
           proxies were solicited pursuant to Regulation 14D under the
           Securities Exchange Act of 1934, (B)  there was no solicitation in
           opposition to management's nominees as listed in the proxy
           statement and (C)  such nominees were elected); (ii) the approval of
           amendments to the Company's Directors Stock Incentive
           Plan; and (iii)  the ratification of the appointment of
           PricewaterhouseCoopers, LLP as independent accountants of the
           Company for the current fiscal year.

           With respect to the election of directors, votes were cast as
           follows:

                        T. Jerome Holleran
                        ------------------

       Votes for                20,616,796
       Withheld                     80,873

                         R. James Macaleer
                         -----------------
       Votes for                20,617,394
       Withheld                     80,275

                          Alan M. Sebulsky
                          ----------------
       Votes for                20,617,815
       Withheld                     79,854


           With respect to other matters, votes were cast as follows:


                                  Approval of Amendments
                                to the Company's Directors
                                  Stock Incentive Plan
                                --------------------------
       Votes for                        19,167,185
       Votes against                     1,017,569
       Abstentions                         512,915

                            Ratification of the Appointment
                              of Independent Accountants
                            -------------------------------
       Votes for                       20,688,457
       Votes against                        4,397
       Abstentions                          4,815

       There were no broker non-votes in respect of these matters.






                                  -24-

</PAGE>


<PAGE>

                    ARROW INTERNATIONAL, INC.


Item 6.    Exhibits and reports on Form 8-K

       (a) Exhibits

           The following exhibits will be filed as part of this Form 10-Q:

                   Exhibit 27.1   *Financial Data Schedule
                                   for the quarter ended
                                   February 29, 2000

                   Exhibit 99.1   Cautionary Statement for Purposes
                                  of the Safe Harbor Provisions of the
                                  Private Securities Litigation Reform
                                  Act of 1995

        (b) Reports on Form 8-K

            No reports on Form 8-K were filed during the
            quarter ended February 29, 2000.



*Not  deemed  filed for purposes of Section 11 of the  Securities
Act  of  1933, Section 18 of the Securities Exchange Act of  1934
and  Section 323 of the Trust Indenture Act of 1939, or otherwise
subject  to the liabilities of such sections and not deemed  part
of any registration statement to which such exhibit relates.



                              -25-

</PAGE>

<PAGE>
                    ARROW INTERNATIONAL, INC.

                            SIGNATURE


Pursuant  to the requirements of the Securities Exchange  Act  of
1934, the Registrant has duly caused this report to be signed  on
its behalf by the undersigned thereunto duly authorized.


                                ARROW INTERNATIONAL, INC.
                                        (Registrant)



Date:  April 13, 2000       By:  /s/  Frederick J. Hirt
                                 -----------------------

                                         (signature)

                                 Frederick J. Hirt
                                 Vice President-Finance and Treasurer
                                 (Principal Financial Officer and
                                 Chief Accounting Officer)










                              -26-
</PAGE>

<PAGE>
                          EXHIBIT INDEX



Exhibit   Description
Number    of Exhibit                  Method of Filing
-------   -----------                 -----------------
27        *Financial Data Schedule     EDGAR
          for the quarter ended
          February 29, 2000


99.1      Cautionary Statement for    Page 28 of this report
          Purposes of the Safe
          Harbor Provisions of the
          Private Securities
          Litigation Reform Act of
          1995






















*Not  deemed  filed for purposes of Section 11 of the  Securities
Act  of  1933, Section 18 of the Securities Exchange Act of  1934
and  Section 323 of the Trust Indenture Act of 1939, or otherwise
subject  to the liabilities of such sections and not deemed  part
of any registration statement to which such exhibit relates.



                              -27-

</PAGE>


<PAGE>                   EXHIBIT 99.1

CAUTIONARY STATEMENT FOR PURPOSES OF THE SAFE HARBOR PROVISIONS
OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

     From  time  to  time, in both written reports  and  in  oral
statements  by  our  senior management,  expectations  and  other
statements are expressed regarding our future performance.  These
forward-looking statements are inherently uncertain and investors
must  recognize  that events could turn out to be different  than
such  expectations  and  statements.  Key factors  impacting  our
current and future performance are discussed in our Annual Report
on  Form 10-K for our fiscal year ended August 31, 1999 and other
filings   with  the  Securities  and  Exchange  Commission   (the
"Commission").   In addition to such information  in  our  Annual
Report  on  Form 10-K and our other filings with the  Commission,
investors   should  consider  the  following  risk   factors   in
evaluating us and our business, as well as in reviewing  forward-
looking  statements contained in our periodic reports filed  with
the  Commission  and  in  oral  statements  made  by  our  senior
management.  Our actual results could differ materially from such
forward-looking  statements due to material risks,  uncertainties
and contingencies, including, without limitation, those set forth
below.

Stringent Government Regulation

     Our products are subject to extensive regulation by the Food
and  Drug  Administration (the "FDA") and, in some jurisdictions,
by   state,  local  and  foreign  governmental  authorities.   In
particular,  we must obtain specific clearance or  approval  from
the  FDA  before  we can market new products or certain  modified
products  in  the  United  States.  With  the  exception  of  one
product,  we have, to date, obtained FDA marketing clearance  for
our  products  only  through  the 510(k)  premarket  notification
process.   Certain of our products under development  and  future
applications,  however, will require approval  through  the  more
vigorous  Premarket  Approval application ("PMA")  process.   The
process  of  obtaining such clearances or approvals can  be  time
consuming and expensive.  We cannot assure you that the FDA  will
grant all clearances or approvals sought by us or that FDA review
will  not  involve delays adversely affecting the  marketing  and
sale  of  our  products.   We  are also  required  to  adhere  to
applicable  regulations setting forth current Good  Manufacturing
Practices ("GMP") which require that we manufacture our  products
and  maintain our records in a prescribed manner with respect  to
manufacturing, testing and control activities.  In  addition,  we
are  required  to comply with FDA requirements for  labeling  and
promotion  of  our products.  Failure to comply  with  applicable
federal,  state,  local  or  foreign laws  or  regulations  could
subject  us  to  enforcement action, including product  seizures,
recalls,  withdrawal of clearances or approvals,  and  civil  and
criminal  penalties,  any  one or more  of  which  could  have  a
material adverse effect on our business, financial condition  and
results  of operations.  Many of the foreign countries  where  we
conduct business have adopted medical device laws and regulations
with  similar  substantive and enforcement provisions.   Federal,
state,  local  and  foreign  laws and regulations  regarding  the
development, manufacture and sale of medical devices are  subject
to  future changes.  We cannot assure you that such changes  will
not  have  a  material adverse effect on our business,  financial
condition and results of operations.




                              -28-

</PAGE>

<PAGE>



Significant Competition and Continual Technological Change

      The markets for medical devices are highly competitive.  We
currently  compete  with many companies in  the  development  and
marketing of catheters and related medical devices.  Some of  our
competitors have access to greater financial and other  resources
than us.

       Furthermore,   the   markets  for  medical   devices   are
characterized  by  rapid  product development  and  technological
change.  Technological advances by one or more of our current  or
future  competitors could render our present or  future  products
obsolete  or  uneconomical.  Our future success will depend  upon
our  ability  to  develop new products and technology  to  remain
competitive  with  other  developers  of  catheters  and  related
medical  devices. Our business strategy emphasizes the  continued
development  and  commercialization  of  new  products  and   the
enhancement  of  existing  products for  the  critical  care  and
cardiac care markets.  We cannot assure you that we will be  able
to  continue to successfully develop new products and to  enhance
existing   products,   to  manufacture  these   products   in   a
commercially   viable  manner,  to  obtain  required   regulatory
approvals  or  to  gain satisfactory market  acceptance  for  our
products.

Cost  Pressures  on Medical Technology and Proposed  Health  Care
Reform

       Our  products  are  purchased  principally  by  hospitals,
hospital  networks  and  hospital buying  groups.   Although  our
products  are used primarily for non-optional medical procedures,
we  believe that the overall escalating cost of medical  products
and  services  has  led and will continue to  lead  to  increased
pressures  upon the health care industry to reduce  the  cost  or
usage  of  certain products and services.  In the United  States,
these  cost  pressures are leading to increased emphasis  on  the
price and cost-effectiveness of any treatment regimen and medical
device.   In  addition, third party payors, such as  governmental
programs,  private insurance plans and managed care plans,  which
are  billed  by  hospitals  for such health  care  services,  are
increasingly negotiating the prices charged for medical  products
and services and may deny reimbursement if they determine that  a
device  was not used in accordance with cost-effective  treatment
methods as determined by the payor, was experimental, unnecessary
or  used for an unapproved indication.  In international markets,
reimbursement  systems  vary  significantly  by  country.    Many
international markets have government managed health care systems
that  control  reimbursement  for  certain  medical  devices  and
procedures  and,  in most such markets, there  also  are  private
insurance systems which impose similar cost restraints. We cannot
assure  you  that hospital purchasing decisions or government  or
private  third party reimbursement policies in the United  States
or  in  international  markets  will  not  adversely  affect  the
profitability of our products.

      In  recent years, several comprehensive health care  reform
proposals have been introduced in the U.S. Congress.  While  none
of these proposals have to date been adopted, the intent of these
proposals was, generally, to expand health care coverage







                              -29-

</PAGE>

<PAGE>


for  the uninsured and reduce the rate of growth of total  health
care   expenditures.   In  addition,  certain  states  have  made
significant  changes to their Medicaid programs and have  adopted
various   measures   to   expand  coverage   and   limit   costs.
Implementation of government health care reform and other efforts
to  control costs may limit the price of, or the level  at  which
reimbursement  is  provided for, our products.   Several  foreign
countries   have  recently  considered,  and  in  some  countries
adopted,  similar  reforms to limit the  growth  of  health  care
costs,  including price regulation.  We anticipate that Congress,
state  legislatures, foreign governments and the  private  sector
will  continue  to  review  and assess  alternative  health  care
delivery  and payment systems.  We cannot predict what additional
legislation  or regulation, if any, relating to the  health  care
industry may be enacted in the future or what impact the adoption
of  any  federal,  state or foreign health care  reform,  private
sector  reform  or  market forces may have on our  business.   We
cannot  assure you that any such reforms will not have a material
adverse effect on the medical device industry in general,  or  on
our business, in particular.

Dependence on Patents and Proprietary Rights

      We  own  numerous U.S. and foreign patents and have several
U.S.  and  foreign  patent applications pending.   We  also  have
exclusive  license  rights  to  certain  patents  held  by  third
parties.  These patents relate to aspects of the technology  used
in certain of our products.  From time to time, we are subject to
legal  actions  involving patent and other intellectual  property
claims.   Successful litigation against us regarding our  patents
or  infringement  of  the patent rights of others  could  have  a
material adverse effect on our business, financial condition  and
results  of operations.  In addition, we cannot assure  you  that
pending patent applications will result in issued patents or that
patents issued to or licensed-in by us will not be challenged  or
circumvented  by competitors or found to be valid or sufficiently
broad  to  protect  our  technology or to  provide  it  with  any
competitive  advantage.   We  also  rely  on  trade  secrets  and
proprietary technology that we seek to protect, in part,  through
confidentiality agreements with employees, consultants and  other
parties.  We cannot assure you that these agreements will not  be
breached,  that  we will have adequate remedies for  any  breach,
that   others   will  not  independently  develop   substantially
equivalent proprietary information or that third parties will not
otherwise gain access to our trade secrets.

      There has been substantial litigation regarding patent  and
other   intellectual  property  rights  in  the  medical  devices
industry.  Historically, litigation has been necessary to enforce
certain   patent  and  trademark  rights  held  by  us.    Future
litigation  may  be  necessary  to  enforce  patent   and   other
intellectual  property rights belonging to  us,  to  protect  our
trade secrets or other know-how owned by us, or to defend ourself
against  claimed  infringement of the rights  of  others  and  to
determine  the scope and validity of our and others'  proprietary
rights.  Any such litigation could result in substantial cost  to
and  diversion  of effort by us.  Adverse determinations  in  any
such  litigation could subject us to significant  liabilities  to
third parties, require us to seek licenses from third parties and
prevent  us from manufacturing, selling or using certain  of  our
products, any one or more of which could have a material  adverse
effect  on  our  business,  financial condition  and  results  of
operations.




                              -30-

</PAGE>

<PAGE>

Risks Associated with International Operations

      We generate significant sales outside the United States and
are  subject  to  risks generally associated  with  international
operations,   such   as   unexpected   changes   in    regulatory
requirements, tariffs, customs, duties and other trade  barriers,
difficulties in staffing and managing foreign operations,  longer
payment  cycles,  problems  in  collecting  accounts  receivable,
political risks, fluctuations in currency exchange rates, foreign
exchange  controls  which  restrict or prohibit  repatriation  of
funds, technology export and import restrictions or prohibitions,
delays   from   customs  brokers  or  government   agencies   and
potentially adverse tax consequences resulting from operating  in
multiple jurisdictions with different tax laws, any one  or  more
of  which  could materially adversely impact the success  of  our
international  operations.   As our revenues  from  international
operations  increase, an increasing portion of our  revenues  and
expenses  will  be  denominated in  currencies  other  than  U.S.
dollars and, consequently, changes in exchange rates could have a
greater  effect on our future operations.  We cannot  assure  you
that such factors will not have a material adverse effect on  our
business,  financial  condition and results  of  operations.   In
addition,  we  cannot  assure  you that  laws  or  administrative
practices  relating  to regulation of medical devices,  taxation,
foreign  exchange or other matters of countries within  which  we
operate  will  not  change.  Any such change could  also  have  a
material adverse effect on our business, financial condition  and
results of operations.

Potential Product Liability

     Our business exposes us to potential product liability risks
which are inherent in the testing and marketing of catheters  and
related medical devices. Our products are often used in intensive
care settings with seriously ill patients.  In addition, many  of
the  medical devices manufactured and sold by us are designed  to
be  implanted  in  the human body for long periods  of  time  and
component  failures,  manufacturing  flaws,  design  defects   or
inadequate  disclosure of product-related risks with  respect  to
these  or other products manufactured or sold by us could  result
in  an  unsafe condition or injury to, or death of, the  patient.
The  occurrence  of  such  a  problem  could  result  in  product
liability claims and/or a recall of, or safety alert relating to,
one  or  more  of our products.  We cannot assure  you  that  the
product liability insurance maintained by us will be available or
sufficient to satisfy all claims made against us or that we  will
be  able to obtain insurance in the future at satisfactory  rates
or  in  adequate  amounts.  Product liability claims  or  product
recalls  in  the  future, regardless of their  ultimate  outcome,
could  result  in  costly litigation and could  have  a  material
adverse effect on our business or reputation or on our ability to
attract and retain customers for our products.

Risks Associated with Derivative Financial Instruments

      As a partial hedge against adverse fluctuations in exchange
rates,  we  periodically  enter into  foreign  currency  exchange
contracts  with certain major financial institutions.   By  their
nature, all such contracts involve risk, including the risk of








                              -31-
</PAGE>

<PAGE>

nonperformance  by counterparties.  Accordingly, losses  relating
to  these contracts could have a material adverse effect upon our
business,  financial condition and results  of  operations.   Our
policy   prohibits   the  use  of  derivative   instruments   for
speculative purposes.

Dependence on Key Management

      Our success depends upon the continued contributions of key
members of our senior management team, certain of whom have  been
with  us since our inception in 1975.  Accordingly, loss  of  the
services of one or more of these key members of management  could
have  a  material adverse effect on our business.  None of  these
individuals has an employment agreement with us.


</PAGE>




















































                              -32-